US FDA permits small Phase II study for Repros' troubled Proellex
This article was originally published in Scrip
The US FDA has lifted its full clinical hold on the development of Repros Therapeutics’ lead product Proellex (telapristone acetate, CDB-4124) to allow the company to run a small Phase II study of lower doses of the drug under a partial hold status.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.